Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
Rhythm Pharmaceuticals announced that seven abstracts, including four late-breaking presentations, were accepted for ENDO 2026, the Endocrine Society’s annual meeting in Chicago. The presentations cover Phase 2 and Phase 3 data for setmelanotide in Prader-Willi syndrome and acquired hypothalamic obesity, as well as one-year weight reduction data for the oral pipeline asset bivamelagon. Additionally, Dr.
Key figures
- Abstracts accepted
- 7
- Pws follow up months
- 6
- Late breaking abstracts
- 4
- Pws trial total patients
- 18
- Pws trial patients updated
- 17
- Bivamelagon follow up years
- 1
- Setmelanotide ho extension years
- 2.5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.